BRPI0916601A2 - método e kit de diagnóstico de uma doença neurodegenerativa, e uso de um anticorpo que se liga a glutaminil ciclase (qc) ou uma isoforma da mesma - Google Patents
método e kit de diagnóstico de uma doença neurodegenerativa, e uso de um anticorpo que se liga a glutaminil ciclase (qc) ou uma isoforma da mesmaInfo
- Publication number
- BRPI0916601A2 BRPI0916601A2 BRPI0916601A BRPI0916601A BRPI0916601A2 BR PI0916601 A2 BRPI0916601 A2 BR PI0916601A2 BR PI0916601 A BRPI0916601 A BR PI0916601A BR PI0916601 A BRPI0916601 A BR PI0916601A BR PI0916601 A2 BRPI0916601 A2 BR PI0916601A2
- Authority
- BR
- Brazil
- Prior art keywords
- isoform
- diagnosing
- binds
- antibody
- kit
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
- G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8515408P | 2008-07-31 | 2008-07-31 | |
US61/085,154 | 2008-07-31 | ||
PCT/EP2009/059951 WO2010012828A2 (en) | 2008-07-31 | 2009-07-31 | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0916601A2 true BRPI0916601A2 (pt) | 2015-11-10 |
BRPI0916601B1 BRPI0916601B1 (pt) | 2021-05-25 |
Family
ID=41256108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0916601-7A BRPI0916601B1 (pt) | 2008-07-31 | 2009-07-31 | Método de diagnóstico de doença de alzheimer (da), neurodegeneração em síndrome de down (nsd) ou comprometimento cognitivo leve (mci) em um indivíduo |
Country Status (16)
Country | Link |
---|---|
US (3) | US20100028918A1 (pt) |
EP (1) | EP2329274B1 (pt) |
JP (1) | JP5677297B2 (pt) |
KR (1) | KR101682728B1 (pt) |
CN (2) | CN103983787A (pt) |
AU (1) | AU2009275869B2 (pt) |
BR (1) | BRPI0916601B1 (pt) |
CA (1) | CA2731933A1 (pt) |
EA (1) | EA025107B1 (pt) |
HK (1) | HK1155813A1 (pt) |
IL (1) | IL210266A (pt) |
MX (1) | MX2011001093A (pt) |
NZ (1) | NZ590658A (pt) |
SG (1) | SG193148A1 (pt) |
WO (1) | WO2010012828A2 (pt) |
ZA (1) | ZA201100177B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013519891A (ja) * | 2010-02-18 | 2013-05-30 | プロビオドルグ エージー | ピログルタミン酸修飾mcp−1を決定することにより炎症性疾患を診断する方法及びグルタミニルシクラーゼの阻害剤のスクリーニング方法 |
SG10201604304RA (en) * | 2011-05-27 | 2016-07-28 | Probiodrug Ag | Radiolabelled glutaminyl cyclase inhibitors |
JP2018501482A (ja) | 2014-12-19 | 2018-01-18 | プロビオドルグ エージー | pGlu−Abetaペプチドの検出のための新規の方法 |
CN104946680A (zh) * | 2015-06-11 | 2015-09-30 | 深圳大学 | 用于表达qc的重组载体及其制备方法、引物、基因工程菌 |
WO2018008764A1 (ja) * | 2016-07-08 | 2018-01-11 | 味の素株式会社 | 軽度認知障害又はアルツハイマー型認知症の評価方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4374316B2 (ja) * | 1993-01-25 | 2009-12-02 | 武田薬品工業株式会社 | β−アミロイドまたはその誘導体に対する抗体およびその用途 |
JP3590468B2 (ja) * | 1996-01-22 | 2004-11-17 | 財団法人 東京都医学研究機構 | アルツハイマー病診断薬 |
CA2487528A1 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
EP1620082B9 (en) * | 2003-05-05 | 2010-08-25 | Probiodrug AG | Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer's disease and down syndrome |
JP5707014B2 (ja) * | 2003-10-15 | 2015-04-22 | プロビオドルグ エージー | グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用 |
US20060094064A1 (en) * | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
EP1713780B1 (en) * | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
EP1869008A1 (en) * | 2005-04-11 | 2007-12-26 | Probiodrug AG | Inhibitors of prolyl endopeptidase |
ES2373048T3 (es) * | 2006-06-08 | 2012-01-30 | Fu Berlin | Análisis para el diagnóstico de la enfermedad de alzheimer basado en la determinación de la proporción de productos de escisión ab de secretasa. |
EA016584B1 (ru) * | 2006-09-21 | 2012-06-29 | Пробиодруг Аг | Новые гены, родственные гену глутаминилциклазы |
SI2121944T1 (sl) | 2007-01-19 | 2011-12-30 | Probiodrug Ag | In vivo presejalni modeli za zdravljenje Alzheimerjeve bolezni in drugih motenj, povezanih s QPCT |
-
2009
- 2009-07-31 US US12/533,099 patent/US20100028918A1/en not_active Abandoned
- 2009-07-31 NZ NZ590658A patent/NZ590658A/en unknown
- 2009-07-31 SG SG2013056478A patent/SG193148A1/en unknown
- 2009-07-31 CN CN201410221835.XA patent/CN103983787A/zh active Pending
- 2009-07-31 CA CA2731933A patent/CA2731933A1/en not_active Abandoned
- 2009-07-31 EP EP09781358.8A patent/EP2329274B1/en active Active
- 2009-07-31 CN CN200980130500.4A patent/CN102112880B/zh active Active
- 2009-07-31 JP JP2011520526A patent/JP5677297B2/ja active Active
- 2009-07-31 WO PCT/EP2009/059951 patent/WO2010012828A2/en active Application Filing
- 2009-07-31 EA EA201100253A patent/EA025107B1/ru not_active IP Right Cessation
- 2009-07-31 KR KR1020117002132A patent/KR101682728B1/ko active IP Right Grant
- 2009-07-31 BR BRPI0916601-7A patent/BRPI0916601B1/pt active IP Right Grant
- 2009-07-31 MX MX2011001093A patent/MX2011001093A/es active IP Right Grant
- 2009-07-31 AU AU2009275869A patent/AU2009275869B2/en active Active
-
2010
- 2010-12-26 IL IL210266A patent/IL210266A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00177A patent/ZA201100177B/en unknown
- 2011-09-26 HK HK11110120.9A patent/HK1155813A1/xx unknown
-
2015
- 2015-03-12 US US14/645,821 patent/US20150247180A1/en not_active Abandoned
-
2016
- 2016-12-14 US US15/378,328 patent/US20170097365A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2329274A2 (en) | 2011-06-08 |
EP2329274B1 (en) | 2015-12-02 |
CA2731933A1 (en) | 2010-02-04 |
CN102112880B (zh) | 2014-06-25 |
US20150247180A1 (en) | 2015-09-03 |
CN103983787A (zh) | 2014-08-13 |
US20100028918A1 (en) | 2010-02-04 |
JP5677297B2 (ja) | 2015-02-25 |
MX2011001093A (es) | 2011-03-15 |
KR101682728B1 (ko) | 2016-12-05 |
NZ590658A (en) | 2012-07-27 |
CN102112880A (zh) | 2011-06-29 |
KR20110049781A (ko) | 2011-05-12 |
ZA201100177B (en) | 2012-02-29 |
AU2009275869A1 (en) | 2010-02-04 |
IL210266A0 (en) | 2011-03-31 |
US20170097365A1 (en) | 2017-04-06 |
JP2011529571A (ja) | 2011-12-08 |
WO2010012828A3 (en) | 2010-05-06 |
WO2010012828A2 (en) | 2010-02-04 |
SG193148A1 (en) | 2013-09-30 |
EA201100253A1 (ru) | 2011-10-31 |
EA025107B1 (ru) | 2016-11-30 |
IL210266A (en) | 2016-04-21 |
HK1155813A1 (en) | 2012-05-25 |
AU2009275869B2 (en) | 2015-05-21 |
BRPI0916601B1 (pt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0720361A2 (pt) | Método para medir aglutinação de uma ou mais partículas em um ensaio de aglutinação induzida por alvo efetuado em uma câmara de reação, e, kit e dispositivo para medir um ou mais parâmetros de aglutinação de partículas em um ensaio de aglutinação induzida por alvo | |
RS54879B1 (sr) | Metode i kompozicije za dijagnoze i prognoze oštećenja bubrega i bubrežne insuficijencije | |
DK1831699T3 (da) | Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme | |
BRPI0916601A2 (pt) | método e kit de diagnóstico de uma doença neurodegenerativa, e uso de um anticorpo que se liga a glutaminil ciclase (qc) ou uma isoforma da mesma | |
DK1859184T3 (da) | Test af sikkerhedsventil | |
FR2904549B1 (fr) | Composition comprenant de la sarsasapogenine | |
WO2008111464A1 (ja) | スプライシング異常を指標とする抗ガン剤の作用検定方法 | |
BRPI0822033A2 (pt) | Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit | |
BR112012019475A8 (pt) | uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra | |
BRPI0809612A2 (pt) | Mancal deslizante de empuxo; e um mecanismo combinado do mancal deslizante de empuxo e uma haste de pistão com mola espiralada | |
DK1994004T3 (da) | 1,4-disubstituerede 3-cyanpyridonderivater og anvendelse af disse som positive allosteriske modulatorer af mglur2-receptorer | |
BRPI0923199B8 (pt) | método para determinar a presença de anticorpos de fixação de complemento | |
BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
BRPI0607323A2 (pt) | composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo | |
BRPI0821600A2 (pt) | Composição farmacêutica, artigo de fabricação, kit de partes, método de combater aterosclerose, ou uma doença cardiovascular associada à aterosclerose, e, uso de um anticorpo | |
BR112012016992A2 (pt) | "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena". | |
WO2008106648A3 (en) | Immunoassays exhibiting a reduction in prozone phenomena | |
DK2021794T3 (da) | Anvendelse af protein S100A 12 som en markør for colorektal cancer | |
BRPI0714642A2 (pt) | "sequências do primer diagnóstico de tsv isolado, par de duas sequências do primer diagnóstico de tsv difenrentes, kit para detecção do tsv, métodos para a detecção da presença do tsv em uma amostra e método para q quantificação da quantidade de tsv em uma amostra" | |
DK2080012T3 (da) | Fremgangsmåder til analyse af testforbindelser på forbundne receptorer. | |
BR112017023726A2 (pt) | detecção de fatores de virulência microbiana na cavidade oral | |
BRPI0814471A2 (pt) | Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo | |
BR112014009223A2 (pt) | método para o diagnóstico da doença de niemann-pick | |
BR112012033163A2 (pt) | ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo'' | |
BR112014031958A2 (pt) | bag3 como marcador de tecido e soro bioquímico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.2 NA RPI NO 2608 DE 29/12/2020 POR TER SIDO INDEVIDA. |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25D | Requested change of name of applicant approved |
Owner name: VIVORYON THERAPEUTICS AG (DE) |
|
B25D | Requested change of name of applicant approved |
Owner name: VIVORYON THERAPEUTICS N.V. (DE) |